FDA approves Aciphex Sprinkle capsules

WOODCLIFF LAKE, N.J. — The Food and Drug Administration has approved a treatment made by Eisai for gastroesophageal reflux disease in children ages 1 year to 11 years, the drug maker said.

Eisai announced the approval of Aciphex Sprinkle (rabeprazole sodium) delayed-release capsules.

"We are proud to offer a new treatment option for young children who suffer from GERD," Eisai president and CEO Lonnel Coats said. "Eisai is committed to keeping the medical needs of patients and their families at the forefront of all that we do as part of our human healthcare corporate mission."